The following is an article I downloaded from urotoday.com in October last year. I gather talzenna has been approved for breast cancer treatment for some time but the outcome from the phase 3 Talepro -2 trail shows great results for prostate cancer. Does anyone know if Pfizer has sought approval for use with prostate cancer?
From Urotoday.com: "Pfizer Inc. announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared with placebo plus XTANDI. The results of the primary endpoint exceeded the pre-specified hazard ratio of 0.696.
Results showed a trend toward improved overall survival, a key secondary endpoint, at the time of the analysis, but these data are not yet mature. Benefits were also observed in other secondary endpoints, including investigator assessed rPFS, prostate specific antigen (PSA) response, time to PSA progression, and overall response rate. Other secondary endpoints are being analyzed. At the time of topline analysis, the safety of TALZENNA plus XTANDI were generally consistent with the known safety profile of each medicine."
Not Tolerating Xtandi 
Xtandi monotherapy is very effective
Off Xtandi, what next?
Xtandi and leg and back aches
Xtandi fighting this beast Cancer
